There were significant differences in age distribution, as well as the frequency of many clinical variables (primary vs. secondary AML, white blood cell count, percentage of blasts and platelets number), cytogenetics (by risk group, simple vs. complex karyotype, or for specific events, such as −5/5q-, −7/7q- and inv16), and for several individual mutations (ASXL1, CEBPA, DNMT3A, EZH2, FLT3 [individually for ITD and D835, and in combination], NPM1, and TP53). This evidence concerns the gene TP53 and acute myeloid leukemia.